Press release

Evonik invests in Hosen Capital Fund III

February 7, 2017

• Boost for venture capital engagement in Asia
• Focus on agriculture and nutrition
• Strong partnership with direct business relevance

Essen, Germany. Evonik is boosting its corporate venturing activities in Asia by investing in the Chinese “Hosen Capital Fund III.” The fund invests in leading businesses and technology companies with a focus on the agriculture and nutrition sector. The parties agreed to keep the amount of the investment sum confidential. “With our investment in the Hosen Capital Fund III, we enter into a strong partnership with direct relevance for our own business activities,” said Bernhard Mohr, head of Venture Capital at Evonik. “At the same time, we expand our engagement in one of the world’s most important venture capital markets.” Fund investments are an essential component of Evonik's venture capital activities.

Evonik’s products and services in the area of animal nutrition play a key role worldwide in the production of healthy and affordable food, while preserving natural resources and reducing the ecological footprint. “Our strategic involvement in the Hosen Capital Fund III gives us access to partnerships with innovative technology start-ups in the Chinese agriculture and nutrition industry, resulting in essential impulses for further business development,” noted Emmanuel Auer, head of Evonik’s Animal Nutrition Business Line.

Evonik plans to invest a total of €100 million in promising start-ups with innovative technologies and in leading specialized venture capital funds as part of its venture capital activities. Regional focuses are Europe, the United States and Asia. Currently, Evonik holds stakes in ten start-ups and five funds.

More information is available at http://venturing.evonik.com/.

Contact

Scarlett Shi

Contact

  • Company information

    Evonik, the creative industrial group from Germany, is one of the world leaders
    in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms. Evonik is active in over 100 countries around the world. In fiscal 2015 more than 33,500 employees generated sales of around €13.5 billion and an operating profit (adjusted EBITDA) of about €2.47 billion.

  • Evonik Industries has been producing specialty chemical products in the Greater China region (Mainland China, Hong Kong and Taiwan) since the late 1970’s; with wide-ranging trading relations already in place prior to this in the region. Evonik regards Greater China as one of the driving forces of the global economy and we consequently endeavor to grow our business in the region. The company now has around 3,000 employees in the Greater China region, the regional sales reached over €1.3 billion in 2015.

  • Disclaimer

    In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.